



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 10th January 2022

Re: Freedom of Information Request 369-2021

Thank you for your email dated the 9th December 2021, requesting information in relation to Urothelial Cancer patients.

The information that you require is as follows:

Question One:

In the past 3 months, how many Urothelial Cancer patients were treated with the below:	Count
a) Atezolizumab	24
b) Carboplatin with Gemcitabine	19
c) Carboplatin single or in any other combination	0
d) Cisplatin with Gemcitabine	11
e) Cisplatin single or in any other combination	0
f) Nivolumab	1
g) Pembrolizumab	1
h) Any other regimen including Paclitaxel - listed below:	21
i) Avelumab	6
ii) Denosumab	2
iii) Fluorouracil + Mitomycin	3
iv) Gemcitabine	3
v) Paclitaxel	6
vi) Ramucirumab	1
i) Any other chemotherapy regimen	0
j) Other active systemic anti-cancer therapy (please state)	0
k) Palliative care only	0

Question Two:

Does your Trust participate in any ongoing clinical trials for the treatment of Urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Yes, details below:

Urothelial Cancer – Open to Recruitment

Project Full title	Recruited
Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations	6

Urothelial Cancer – Follow-up

Project Full title	Recruited
A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer	4
RANGE - Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab plus Docetaxel Versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy	12
A Phase II, 2-Arm MultiCenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable Urothelial Cancer with FGFR Genomic Alterations	1
A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	10
An Open-Label, Randomised Phase 3 Study to Evaluate Enfortumab Vedotin vs. Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)	5
POUT - A Phase III randomised trial	6

**of PeriOperative chemotherapy
versus sUrveillance in upper Tract
urothelial cancer**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY.

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind regards

Margaret Moore
Information Governance Administrator
Contact Email: ccf-tr.foi@nhs.net